ScholarIQanswers from OpenAlex & ORCID
Peter J. O’Dwyer
ResearcherPublications, citations & collaboration network
Peter J. O’Dwyer is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Peter J. O’Dwyer have?
ScholarIQindexed works
Peter J. O’Dwyer has 768 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Peter J. O’Dwyer have?
ScholarIQcitation count
Peter J. O’Dwyer has 42,712 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Peter J. O’Dwyer?
ScholarIQh-index
Peter J. O’Dwyer has an h-index of 87 in OpenAlex.
What is the i10-index of Peter J. O’Dwyer?
ScholarIQi10-index
Peter J. O’Dwyer has an i10-index of 296 in OpenAlex.
What is the ORCID of Peter J. O’Dwyer?
ScholarIQorcid
The ORCID for Peter J. O’Dwyer is on the source record.
What is the OpenAlex record for Peter J. O’Dwyer?
ScholarIQopenalex
The OpenAlex for Peter J. O’Dwyer is on the source record.
What are the most-cited papers on Peter J. O’Dwyer?
ScholarIQmost cited works
Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer
Scott Kopetz, Jayesh Desai, Emily Chan, J. Randolph Hecht, Peter J. O’Dwyer, Dipen M. Maru, Van K. Morris, Filip Jankú, Arvind Dasari, Woonbok Chung, Jean‐Pierre J. Issa, Peter Gibbs, Brian P. James, Garth Powis, K. B. Nolop, Suman Bhattacharya, Leonard B. Saltz
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, Michael S. Gordon, Nicholas J. Vogelzang, Douglas J. DeMarini, Peng Sun, Christopher Moy, Stephen A. Szabo, Lori Roadcap, Vijay Peddareddigari, Peter F. Lebowitz, Ngocdiep T. Le, Howard A. Burris, Wells A. Messersmith, Peter J. O’Dwyer, Kevin B. Kim, Keith T. Flaherty, Johanna C. Bendell, René González, Razelle Kurzrock, Leslie A. Fecher
Combined MTOR and autophagy inhibition
Reshma Rangwala, Yunyoung C Chang, Janice Hu, Kenneth M. Algazy, Tracey L. Evans, Leslie A. Fecher, Lynn M. Schuchter, Drew A. Torigian, Jeffrey T Panosian, Andrea B. Troxel, Kay-See Tan, Daniel F. Heitjan, Angela DeMichele, David J. Vaughn, Maryann Redlinger, Abass Alavi, Jonathon Kaiser, Laura Pontiggia, Lisa E. Davis, Peter J. O’Dwyer, Ravi K. Amaravadi
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma
Reshma Rangwala, Robert D. Leone, Yunyoung C Chang, Leslie A. Fecher, Lynn M. Schuchter, Amy Kramer, Kay-See Tan, Daniel F. Heitjan, Glenda Rodgers, Maryann Gallagher, Shengfu Piao, Andrea B. Troxel, Tracey L. Evans, Angela DeMichele, Katherine L. Nathanson, Peter J. O’Dwyer, Jonathon Kaiser, Laura Pontiggia, Lisa E. Davis, Ravi K. Amaravadi
Gene Expression Patterns in Ovarian Carcinomas
Marci E. Schaner, Douglas T. Ross, Giuseppe Ciaravino, Thérese Sørlie, Olga G. Troyanskaya, Maximilian Diehn, Yan C. Wang, George E. Durán, Thomas L. Sikic, Sandra Caldeira, Hanne Skomedal, I‐Ping Tu, Tina Hernandez‐Boussard, Steven W. Johnson, Peter J. O’Dwyer, M.J. Fero, Gunnar B. Kristensen, Anne‐Lise Børresen‐Dale, Trevor Hastie, Robert Tibshirani, Matt van de Rijn, Nelson N.H. Teng, Teri A. Longacre, David Botstein, Patrick O. Brown, Branimir I. Šikić